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Inosine 50-monophosphate dehydrogenase (IMPDH) is a promising target for
the treatment of Cryptosporidium infections. Here, the structure of C. parvum
IMPDH (CpIMPDH) in complex with inosine 50-monophosphate (IMP) and
P131, an inhibitor with in vivo anticryptosporidial activity, is reported. P131
contains two aromatic groups, one of which interacts with the hypoxanthine ring
of IMP, while the second interacts with the aromatic ring of a tyrosine in the
adjacent subunit. In addition, the amine and NO2 moieties bind in hydrated
cavities, forming water-mediated hydrogen bonds to the protein. The design of
compounds to replace these water molecules is a new strategy for the further
optimization of C. parvum inhibitors for both antiparasitic and antibacterial
applications.
1. Introduction
Cryptosporidium parasites are protozoan pathogens of
increasingly recognized importance in both the developing
and the developed world (Striepen, 2013). Cryptosporidiosis
is a major cause of morbidity in infants and malnutrition in
young children in Africa and Asia, and is a major cause of
waterborne disease in North America and Europe. Infections
are self-limiting in immunocompetent individuals, but can be
chronic and fatal in immunocompromised patients (Checkley
et al., 2014). In addition, Cryptosporidium oocysts are resistant
to commonly used methods of water treatment and are readily
available, making this organism a potential weapon for
bioterrorism. The potential damage of such an incident was
illustrated in the naturally occurring outbreak in Milwaukee in
1993, where 400 000 cases were reported and an estimated $96
million in damages were incurred.
Nitazoxanide is the only FDA-approved drug for the
treatment of cryptosporidiosis (Checkley et al., 2014). It has
limited efficacy in immunocompetent individuals and no effi-
cacy in immunocompromised patients. High doses of paromo-
mycin have anticryptosporidial activity in mice, where nita-
zoxanide is not effective (Tzipori et al., 1994; Baishanbo et al.,
2006), but has not proved effective in humans (Hewitt et al.,
2000). Thus, there is a critical need for new chemotherapy to
treat Cryptosporidium infections.
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Cryptosporidium parasites have a very streamlined purine-
biosynthetic pathway that relies on the salvage of adenosine
from the host (Striepen et al., 2004). Adenosine is converted
into guanine nucleotides in a process that requires IMP
dehydrogenase (IMPDH) activity. Curiously, the Cryptospor-
idium gene for IMPDH appears to have been obtained from
bacteria via lateral transfer, so that the parasite enzyme is very
different from the host ortholog. IMPDH is a clinically vali-
dated target for immunosuppressive, anticancer and antiviral
therapy (Hedstrom, 2009). The IMPDH reaction involves two
chemical transformations (Hedstrom, 2009). The first step is
nucleophilic attack of the active Cys219 at the C2 position of
IMP, followed by hydride transfer to form the covalent inter-
mediate E-XMP* and NADH. The reduced cofactor dissoci-
ates from the enzyme and the mobile active-site flap (residues
302–330) folds into the cofactor site, positioning the catalytic
Arg315 to activate water for the hydrolysis of E-XMP* to
yield the product xanthosine 50-monophosphate (XMP).
IMPDH is a homotetramer with square-planar symmetry. The
four active sites are located near the subunit interfaces. The
IMP site is contained within a monomer, and the residues
that contact IMP are strongly conserved among all IMPDHs
(Hedstrom, 2009). The nicotinamide portion of the cofactor
site also lies within the same monomer as IMP, and is also
strongly conserved, as expected given that this is the site
of chemical transformation. However, the position of the
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Figure 1
(a) Structure of P131 and other cpIMPDH inhibitors. The numbering scheme is shown in italics. (b) 2mFo  DFc electron-density map for P131
contoured at the 1 level. The inhibitor is shown in ball-and-stick representation. (c) Structure of the CpIMPDH tetramer. Subunit A is in tan, subunit B
is in light blue, subunit C is in pink and subunit D is in light green. IMP and P131 are shown as spheres with the following color coding: carbon, cyan for
IMP and magenta for P131; oxygen, red; nitrogen, blue; phosphorus, orange; chlorine, green. (d) Superposition of the individual monomers. Dashed lines
indicate disordered regions. This figure was produced with UCSF Chimera (Pettersen et al., 2004).
adenosine portion of the cofactor site varies widely among
IMPDHs from different organisms. The adenosine site of
eukaryotic IMPDHs is largely within the same monomer as
the IMP site (Colby et al., 1999; Prosise & Luecke, 2003), but in
prokaryotic IMPDHs the adenosine portion of NAD+ binds in
a pocket in the adjacent subunit (Makowska-Grzyska et al.,
2015).
We have been engaged in a program to design selective
inhibitors of C. parvum IMPDH (CpIMPDH) as potential
anticryptosporidial agents (Gorla et al., 2012, 2013, 2014;
Johnson et al., 2013; Kirubakaran et al., 2012; MacPherson et
al., 2010, Maurya et al., 2009; Sharling et al., 2010; Sun et al.,
2014; Umejiego et al., 2004, 2008). Compound P131 is the most
promising compound to arise from this effort (Fig. 1a), with
superior activity to nitazoxanide and paromomycin in a mouse
model of acute disease (Gorla et al., 2014).
The prokaryotic origin of CpIMPDH suggested that these
inhibitors might also be effective against IMPDHs from
pathogenic bacteria (Gollapalli et al., 2010). The CpIMPDH
inhibitor collection does contain many potent inhibitors of
Bacillus anthracis IMPDH, but only a few of these compounds
possess antibacterial activity (Mandapati et al., 2014). The
CpIMPDH inhibitors are generally more hydrophobic, with
less polar surface area, than antibiotics (O’Shea & Moser,
2008), which suggests that they do not efficiently enter
bacteria. Enzyme–inhibitor structures provide important
information for the further modification of CpIMPDH inhi-
bitors both for antiparasitic and antibacterial activities.
Here, we report the structure of the enzyme–IMP–P131
complex. This information will facilitate the further optimi-
zation of CpIMPDH inhibitors for the treatment of crypto-
sporidiosis.
2. Materials and methods
Unless otherwise noted, all reagents and solvents were
purchased from commercial sources and were used without
further purification. Compound P131 was synthesized as
described previously (Gorla et al., 2012).
2.1. Protein production and crystallization
The coding sequence for CpIMPDH was amplified by
PCR and cloned into pMCSG7 vector (Stols et al., 2002) as
described in Gorla et al. (2013). The recombinant construct
produced a fusion protein with an N-terminal His6 tag and a
TEV protease recognition site (ENLYFQ#S) (Table 1). The
fusion protein was expressed in Escherichia coli strain
BL21(DE3) harboring the pMAGIC plasmid encoding one
rare E. coli Arg tRNA (covering the codons AGG/AGA) in
the presence of 100 mg ml1 ampicillin and 30 mg ml1 kana-
mycin (Kim et al., 2011). The cells were grown in enriched M9
medium at 37C followed by overnight induction with 0.5 mM
isopropyl -d-1-thiogalactopyranoside (IPTG) at 18C. Cells
were harvested, resuspended in lysis buffer (50 mM HEPES,
pH 8.0, 500 mM KCl, 20 mM imidazole, 1.5 mM TCEP, 5%
glycerol) and stored at 80C. CpIMPDH protein was puri-
fied according to a standard protocol (Makowska-Grzyska et
al., 2014). The protocol included cell lysis by sonication and
nickel-affinity chromatography on an A¨KTAxpress system
(GE Healthcare Life Sciences) followed by His6-tag cleavage
using recombinant TEV protease (Blommel & Fox, 2007)
and additional Ni2+-affinity chromatography to remove the
protease, the uncut protein and the affinity tag. In the final
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Table 1
Protein-production information.
Source organism C. parvum Iowa II
CryptoDB ID cgd6_20
CryptoDB sequence MGTKNIGKGLTFEDILLVPNYSEVLPREV-
SLETKLTKNVSLKIPLISSAMDTVTEH-
LMAVGMARLGGIGIIHKNMDMESQVNE-
VLKVKNWISNLEKNESTPDQNLDKEST-
DGKDTKSNNNIDAYSNENLDNKGRLRV-
GAAIGVNEIERAKLLVEAGVDVIVLDS-
AHGHSLNIIRTLKEIKSKMNIDVIVGN-
VVTEEATKELIENGADGIKVGIGPGSI-
CTTRIVAGVGVPQITAIEKCSSVASKF-
GIPIIADGGIRYSGDIGKALAVGASSV-
MIGSILAGTEESPGEKELIGDTVYKYY-
RGMGSVGAMKSGSGDRYFQEKRPENKM-
VPEGIEGRVKYKGEMEGVVYQLVGGLR-
SCMGYLGSASIEELWKKSSYVEITTSG-
LRESHVHDVEIVKEVMNYSK
CSGID Clone ID IDP92622
Cloning/expression vector pMCSG7
Expression host E. coli BL21(DE3) pMAGIC†
Complete amino-acid sequence of
the construct produced‡
HHHHHHENLYFQ^SNAMGTKNIGKGLTFE-
DILLVPNYSEVLPREVSLETKLTKNVS-
LKIPLISSAMDTVTEHLMAVGMARLGG-
IGIIHKNMDMESQVNEVLKVKNSGGLR-
VGAAIGVNEIERAKLLVEAGVDVIVLD-
SAHGHSLNIIRTLKEIKSKMNIDVIVG-
NVVTEEATKELIENGADGIKVGIGPGS-
ICTTRIVAGVGVPQITAIEKCSSVASK-
FGIPIIADGGIRYSGDIGKALAVGASS-
VMIGSILAGTEESPGEKELIGDTVYKY-
YRGMGSVGAMKSGSGDRYFQEKRPENK-
MVPEGIEGRVKYKGEMEGVVYQLVGGL-
RSCMGYLGSASIEELWKKSSYVEITTS-
GLRESHVHDVEIVKEVMNYSK
Molecular weight (Da) 38459 (40077 with His6 tag)
Extinction coefficient§ (M1 cm1)/
Abs 0.1% (= 1 g l1)
0.569 (0.583 with His6 tag)
† Kim et al. (2011). ‡ The cloning tag is italicized, with the TEV protease site denoted
‘^’. This construct lacks residues 90–134 compared with the sequence deposited in
CryptoDB. These residues were replaced with Ser-Gly-Gly (underlined). § Calculated
using ProtParam for the reduced protein sequence (Gasteiger et al., 2005).
Table 2
Crystallization.
Method Sitting-drop vapor diffusion
Plate type Greiner Bio-One 96-well CrystalQuick
standard profile, 3 round wells, flat
bottom
Temperature (K) 289
Protein concentration (mg ml1) 13.4
Buffer composition of protein
solution
20 mM HEPES pH 8.0, 150 mM KCl,
1.5 mM TCEP
Composition of reservoir solution 0.1M Bicine–NaOH pH 9.0, 20% PEG
6000
Cryocondition 0.1M Bicine–NaOH pH 9.0, 20% PEG
6000, 15% glycerol
Volume and ratio of drop 1:1 (0.4:0.4 ml)
Volume of reservoir (ml) 135
step, the protein was dialyzed against crystallization buffer
consisting of 20 mM HEPES pH 8.0, 150 mM KCl, 1.5 mM
TCEP, concentrated, flash-cryocooled and stored in liquid
nitrogen. Crystallizations were set up with the help of a
Mosquito liquid dispenser (TTP LabTech). Protein samples
used for crystallization consisted of 13.4 mg ml1 protein in
crystallization buffer (as above), 5 mM IMP, 1.5 mM P131.
Diffraction-quality crystals appeared at 16C in 0.1M Bicine–
NaOH pH 9.0, 20%(w/v) PEG 6000 (Table 2). The crystals
were mounted on CryoLoops (Hampton Research) and flash-
cooled in liquid nitrogen. The cryoprotectant consisted of
0.1M Bicine–NaOH pH 9.0, 20%(w/v) PEG 6000, 15%
glycerol.
2.2. Data collection and structure determination
Diffraction data were collected at 100 K on the 19-ID
beamline of the Structural Biology Center (SBC) at the
Advanced Photon Source (APS), Argonne National Labora-
tory (Rosenbaum et al., 2006). Data were collected at a single
wavelength of 0.97931 A˚ (12.6603 keV) to 2.05 A˚ resolution
from a single crystal of CpIMPDH complexed with IMP and
P131. The crystal was exposed for 3 s per 1.0 rotation in !
at a crystal-to-detector distance of 300 mm. The data were
recorded on an ADSC Q315r CCD detector scanning 190.
The SBC-Collect program was used for data collection and
visualization. Data collection, integration and scaling were
performed with the HKL-3000 program package (Minor et al.,
2006). A summary of the crystallographic data is presented in
Table 3.
The structure was determined by molecular replacement
using the structure of CpIMPDH (PDB entry 3ffs;
MacPherson et al., 2010) as a search model with theHKL-3000
suite using data to 3.0 A˚ resolution (Bricogne et al., 2003;
Minor et al., 2006). The initial model contained four protein
chains of the search model, and there was extra electron
density for additional protein residues that were not part of
the search model. The presence of IMP and P131 in the active
site was apparent from the initial electron-density map (Fo).
Extensive manual model building with Coot (Emsley &
Cowtan, 2004) and subsequent refinement using phenix.refine
(Bricogne et al., 2003; Afonine et al., 2012) were performed
against the full data set to 2.05 A˚ resolution until the structure
converged to an R factor (Rwork) of 0.187 and an Rfree of 0.229
with an r.m.s.d. on bond distances of 0.004 A˚ and an r.m.s.d. on
bond angles of 0.864. The asymmetric unit contained four
protein chains (A, B, C and D), with residues 1–392 for all
chains and a Ser-Gly-Gly linker inserted in place of residues
90–134 (MacPherson et al., 2010). Several N- and C-terminal
amino acids, including the N-terminal Ser-Asn-Ala introduced
during cloning (Eschenfeldt et al., 2010), were missing because
of disorder. In addition, several residues within the active-site
flap were disordered and were not modeled. These included
residues 311–324 in chains A, B and D and 310–325 in chain C.
The final model also contained four IMP molecules, four P131
molecules, five ethylene glycol molecules, one glycerol mole-
cule and 340 ordered water molecules. The stereochemistry of
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Table 3
Data-collection and processing statistics.
Values in parentheses are for the highest resolution shell.
No. of crystals 1
Beamline SBC 19-ID, APS
X-ray wavelength (A˚) 0.97931
Temperature (K) 100
Detector ADSC Quantum 315r
Crystal-to-detector distance (mm) 300
Total rotation range () 190
Rotation per image () 1.0
Exposure time per image (s) 3
Space group P21
Unit-cell parameters (A˚, ) a = 89.19, b = 91.83, c = 92.02,
 = 90,  = 103.75,  = 90
Resolution range (A˚) 40.57–2.05 (2.09–2.05)
Total No. of observations 349609
No. of unique reflections 89862 (4514)
hI/(I)i 12.66 (2.02)
Data completeness (%) 99.9 (99.6)
Rmerge† (%) 14.0 (69.5)
Rp.i.m.(I) (%) 7.9 (43.4)
Wilson B factor (A˚2) 27.5
Multiplicity 3.9 (3.3)
Mosaicity () 0.503–1.367
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of
the ith measurement of an equivalent reflection with indices hkl.
Table 4
Refinement statistics.
Values in parentheses are for the highest resolution shell.
Resolution range (A˚) 40.57–2.053 (2.076–2.053)
Reflections used (working/free) 85300/4499 (2661/139)
Data completeness (%) 99.6 (93.0)
R factor†/Rfree (%) 18.7/22.9 (26.7/31.8)
Total No. of non-H atoms in asymmetric unit 10414
No. of protein atoms 10312
No. of heteroatoms
P131 120
IMP 92
Glycerol 24
PEG 14
No. of water molecules 339
R.m.s.d. from ideal geometry
Bond lengths (A˚) 0.004
Bond angles () 0.864
Average B factors (A˚2)
Overall 36.1
Protein atoms
All 36.0
Main chain 32.4
Side chain 38.4
Water molecules 40.4
Ligand atoms
P131 39.4
IMP 26.1
Solvent/cryoprotectant molecules
Glycerol 62.9
PEG 65.4
Ramachandran statistics (%)
Most favored 97.3
Outliers 0.0
MolProbity scores
Rotamer outliers 0.9
Clashscore 2.59
Overall score 1.15
PDB code 4rv8
† R =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj, where Fobs and Fcalc are observed and calculated
structure factors, respectively.
the structure was checked with PROCHECK (Laskowski et
al., 1993) and a Ramachandran plot. Refinement statistics are
shown in Table 4. Atomic coordinates and experimental
structure factors of the structure have been deposited in the
PDB as entry 4rv8.
3. Results and discussion
The structure of CpIMPDH in complex with IMP and P131
was solved at 2.05 A˚ resolution using molecular replacement
with the structure of apo CpIMPDH (PDB entry 3ffs) as the
search model (Table 4). Density for P131 is clearly visible in all
four subunits (Fig. 1b). The unit cell contains a single tetramer
with D4 symmetry (Fig. 1c). The four subunits are nearly
identical, with r.m.s.d.s ranging between 0.15 A˚ (chain A
versus chains B, C and D) and 0.16 A˚ (chain C versus chains B
and D) (Fig. 1d). Residues 311–324, which are part of the
active-site flap (see below), and residues 378–387 near the
C-terminus are disordered in all four subunits. In addition,
residues 310 and 325 are disordered in chain C.
The conformation and interactions of IMP in the P131
complex are essentially identical to those observed in the
previously reported complexes of CpIMPDH with C64, Q21
and N109 (Fig. 2a; MacPherson et al., 2010; Gorla et al., 2013;
Sun et al., 2014), as well as those in the complexes of Bacillus
anthracis, Campylobacter jejuni and Clostridium perfringens
IMPDHs with various CpIMPDH inhibitors (Makowska-
Grzyska et al., 2015).
As observed with other CpIMPDH inhibitors, P131 binds in
the cofactor site, spanning both the nicotinamide and adeno-
sine subsites (Fig. 2b). The left-side aromatic ring (Fig. 1a)
binds in the nicotinamide subsite, which is a pocket formed
by IMP and residues Ser164-Ala165, Asn191, Gly212–Gly214,
the catalytic Cys219, Thr221, Met302-Gly303, Met308, Glu329
and Tyr3580 (where a prime denotes a residue from the
neighboring subunit). The electron density indicates that
Cys219 has oxidized to the sulfenic acid, as often occurs with
reactive cysteine residues. Similar oxidation of the catalytic
Cys was observed in the structures of Tritrichomonas foetus
IMPDH (Prosise & Luecke, 2003; Prosise et al., 2002). Despite
this modification, the position of Cys219 is very similar to that
observed in other CpIMPDH–inhibitor complexes (Fig. 3a).
The oxime group of P131 lies across the hypoxanthine ring of
IMP, while the N5 amine forms hydrogen bonds to the main-
chain carbonyl O atom of Gly212 and N3 of IMP in all of the
subunits (Fig. 3). The amine also interacts with water mole-
cules to create a hydrogen-bonding network that extends to
the 20-OH of IMP, the sulfenic acid of Cys219, Ala165 N,
Gly212 O, Gly214 N, Thr221 OG, Asp252 O and Tyr358 OH0.
While the protein and inhibitor conformations are nearly
identical in this region in all four subunits, the water occu-
pancy varies slightly. WAT213, WAT282 and WAT316
(numbering in chainsA, B andD, respectively) form hydrogen
bonds to Tyr358 OH0 and Ala165 O in chains A, B and D, but
this water is absent in chain C (Fig. 2b). Curiously, despite
these many interactions, the presence of the alkylamine
decreases the inhibitor potency by a factor of 30 versus the
corresponding oxime (IC50 = 0.66 nM for P96 versus 20 nM for
P131; Gorla et al., 2012).
Also as observed with other CpIMPDH inhibitors
(MacPherson et al., 2010; Gorla et al., 2013; Sun et al., 2014),
P131 bends in the linker region so that the plane of the right-
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Figure 2
Substrate-binding and cofactor-binding sites. (a) The IMP site of
CpIMPDH in complex with inhibitors. Residues in contact with IMP
are shown. P131, PDB entry 4rv8 (pink); C64, PDB entry 3khj (green;
MacPherson et al., 2010); Q21, PDB entry 4ixh (blue; Gorla et al., 2013);
N109, PDB entry 4qj1 (tan; Center for Structural Genomics of Infectious
Diseases, Sun et al., 2014). The B subunit is shown in all four cases. (b)
Superposition of the CpIMPDH–IMP–P131 complex (AD dimer, pink)
with the IMP–NAD+ complex of V. cholerae IMPDH (AA dimer, tan;
PDB entry 4qne; Center for Structural Genomics of Infectious Diseases,
Makowska-Grzyska et al., 2015). P131 is shown in stick representation
with C atoms in magenta. NAD+ is shown in ball-and-stick representation
with C atoms in cyan. The residues that contact NAD+ are shown, with
the exceptions of IMP, Cys219 and Met302-Gly303, which were omitted
for clarity (CpIMPDH numbering). This figure was produced with UCSF
Chimera (Pettersen et al., 2004).
side aromatic moiety is almost perpendicular to the left-side
aromatic moiety (Figs. 1d, 3b and 3c). Both urea N atoms of
P131 form hydrogen bonds to Glu329 OE2 in all four subunits
(Fig. 3b and 3c). Analogous interactions with Glu329 are
observed with other CpIMPDH inhibitors. In addition, water-
mediated hydrogen bonds are found between the urea N1
atom and Val327 O as well as between the urea carbonyl O
atom and Ala165 N.
The right-side aromatic ring binds in the adenosine subsite
formed by residues Ser220, Val240-Leu250-Pro260, Ser164-
Ala165-His166, Ser3540 and Gly3570-Tyr3580 (Makowska-
Grzyska et al., 2015). As noted above, this subsite is highly
divergent, accounting for the selectivity of the CpIMPDH
inhibitors. The analogous residues in human IMPDH type 2
are Ile420, Phe440-Thr450-Ala460, Ser275-Ser276-Gln277,
His466 and Gln4690-Asp4700. As observed with the primary
amine, the NO2 group binds in a hydrophilic pocket. In
subunits A, C and D, the NO2 group is roughly parallel to the
aromatic ring and forms water-mediated hydrogen bonds
to Ser22 O0, Val24 O0, Ser164 OG, His166 O, Ser169 O and
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Figure 3
Interactions of P131 with CpIMPDH. (a) Interactions of the oxime and alkylamine. P131 is displayed in ball-and-stick representation and the protein
residues are in ribbon representation with side chains depicted as sticks. Hydrogen bonds are shown in cyan. The dimer formed by subunits A and D is
shown in tan and the corresponding waters are shown in brown. The BA dimer is shown in light blue and the corresponding waters are shown in dark
blue. The CB dimer is shown in pink and the corresponding waters are shown in magenta. TheDC dimer is shown in light green and the waters are shown
in dark green. Residues within 5 A˚ of P131 are shown, with the exceptions of Asn191, residues 327–329 and the side chains of His166, Ile213 and Asn252,
which have been omitted for clarity. (b) Interactions of the urea and the right side of P131 in the AD, CB and DC dimers. The color scheme is as above.
(c) Interactions of the urea and the right side of P131 in the BC dimer. The color scheme is as above. (d) Interaction of the P131 Cl atom with the
carbonyl O atom of Gly3570. The color scheme is the same as above. Hydrogen bonds are shown in cyan. The halogen bond is shown as a black dashed
line. This figure was produced with UCSF Chimera (Pettersen et al., 2004).
Asn171 N and ND2. In contrast, the NO2 group is perpendi-
cular to the ring in subunit B and forms a hydrogen bond
directly to Ser164 OG (Figs. 2c and 2d).
The P131 Cl atom interacts with the carbonyl O atom of
Gly3570 (Fig. 3d; average distance 3.33  0.12 A˚), which
suggests the presence of a halogen bond (expected distance
3.0–3.40 A˚; Bissantz et al., 2010). The C—Cl  O and Cl  O—
C angles are compatible with halogen-bond formation with the
 system of the carbonyl acting as the donor (128 and 82,
respectively, versus C—Cl  O  120 and 180  Cl  O—C
 70; Bissantz et al., 2010; Voth et al., 2009; Vallejos et al.,
2012). The Gly3570 carbonyl is further polarized by hydrogen
bonds to Ser22 OG0 (average distance 2.85  0.06 A˚) and
Gly360 N0 (average distance 3.19  0.06 A˚). The Gly3570–
Ser22 OG0 hydrogen bond is at approximately 90 relative to
the halogen bond, similar to the angle between other pairs of
halogen and hydrogen bonds.
The water-mediated hydrogen-bonding networks of both
the left-side alkylamine and the right-side NO2 group offer
many opportunities for further inhibitor optimization. In
particular, the repurposing of CpIMPDH inhibitors as anti-
bacterial agents requires the introduction of additional
polarity (Mandapati et al., 2014), which might be attained by
extending the inhibitor to replace water in these networks.
Efforts in this area are ongoing.
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